In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or even the individuals are not able to tolerate the study drugs. after which encourage H3K27Ac at this area. Chromatin hyperacetylation could increase the https://daltonwlyky.aboutyoublog.com/34753236/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options